Status:
COMPLETED
Bioequivalence Study of Metformin 750 mg Tablets XR Versus Glucophage® Long 750 mg Tablets XR In Normal Healthy Subjects Under Fasting and Fed Conditions
Lead Sponsor:
Geropharm
Conditions:
Bioequivalence
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
Bioequivalence Study of 2 formulation of metformin (Metformin GEROPHARM vers. Glucophage® Long Merck )
Detailed Description
Study to evaluate the bioequivalence of orally administered metformin preparations, Extended release tablets, 750 mg in normal healthy subjects under fasting and fed conditions
Eligibility Criteria
Inclusion
- Signed informed consent form.
- Healthy male and female subjects aged 18 to 45 years.
- Verified diagnosis is "healthy" according to data Standard clinical, laboratory and Instrumental methods of examination.
- Have a body mass index between 18,5 and 27 kg/m2.
- Females must have a negative pregnancy test.
- Subjects must use, with their partner, methods of highly effective contraception throughout the study and 30 days after the end of study.
Exclusion
- History of serious allergic problems/events
- Medicinal intolerance.
- History of allergic reactions to memantine or investigator's product components
- Any acute and chronic diseases of the cardiovascular system, cardiovascular, bronchopulmonary, neuroendocrine systems, as well as diseases of the gastrointestinal tract, liver, kidneys, blood.
- Acute infectious diseases in less than 4 weeks before the start of the study.
- Subjects who have taken medication 4 weeks preceding before the study.
- Subjects who have taken any drugs known effects on hemodynamics or to induce or inhibit hepatic drug metabolism within 30 days prior to administration of the study medication (examples of inducers: barbiturates, omeprazole, etc.).
- Donation of plasma (450 mL or more) within 2 month prior to administration of the study medication.
- History of significant alcohol or drugs abuse or any indication of the regular use of more than 10 units of alcohol per week (1 Unit = 200 mL of wine or 500 mL of beer or 50 mL of alcohol 40%).
- Smokers.
- Participation in other clinical training is less than than for 3 months before the study.
- Lack of signed informed consent form.
- ECG or vital signs abnormalities (clinically significant).
- Positive testing for alcohol, drugs, pregnancy.
- Dehydration due to diarrhea, vomiting, or other causes within the last 24 hours before the start of the study.
- Any diet, for example, vegetarian, for 2 weeks before taking the study medications.
- Women with preserved reproductive potential who have unprotected sexual intercourse with an unsterilized male partner within 30 days prior to taking the study medication.
- Heart rate below 60 or above 80 beats per minute.
- Systolic blood pressure less than 110 mm Hg or more than 139 mm Hg.
- Diastolic blood pressure less than 70 mm Hg or more than 89 mm Hg.
Key Trial Info
Start Date :
June 15 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 22 2017
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT03452306
Start Date
June 15 2017
End Date
July 22 2017
Last Update
July 3 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yarosslavl Clinical Hospital #3
Yaroslavl, Russia, 150007